Top

Published in:

Open Access 01-02-2011 | Original Article

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

Authors: Rikke Sick Andersen, Rikke Bæk Sørensen, Cathrin Ritter, Inge Marie Svane, Jürgen C. Becker, Per thor Straten, Mads Hald Andersen

Published in: Cancer Immunology, Immunotherapy | Issue 2/2011

Abstract

With the aim to identify cyclin B1-derived peptides with high affinity for HLA-A2, we used three in silico prediction algorithms to screen the protein sequence for possible HLA-A2 binders. One peptide scored highest in all three algorithms, and the high HLA-A2-binding affinity of this peptide was verified in an HLA stabilization assay. By stimulation with peptide-loaded dendritic cells a CTL clone was established, which was able to kill two breast cancer cell lines in an HLA-A2-dependent and peptide-specific manner, demonstrating presentation of the peptide on the surface of cancer cells. Furthermore, blood from cancer patients and healthy donors was screened for spontaneous T-cell reactivity against the peptide in IFN-γ ELISPOT assays. Patients with breast cancer, malignant melanoma, or renal cell carcinoma hosted powerful and high-frequency T-cell responses against the peptide. In addition, when blood from healthy donors was tested, similar responses were observed. Ultimately, serum from cancer patients and healthy donors was analyzed for anti-cyclin B1 antibodies. Humoral responses against cyclin B1 were frequently detected in both cancer patients and healthy donors. In conclusion, a high-affinity cyclin B1-derived HLA-A2-restricted CTL epitope was identified, which was presented on the cell surface of cancer cells, and elicited spontaneous T-cell responses in cancer patients and healthy donors.

Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207CrossRefPubMed

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332CrossRefPubMed

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327CrossRefPubMed

Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55:1294–1298CrossRefPubMed

Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112–120PubMed

Andersen MH, Svane IM, Becker JC, thor Straten P (2007) The universal character of the tumor-associated antigen survivin. Clin Cancer Res 13:5991–5994CrossRefPubMed

Vonderheide RH (2008) Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 90:173–180CrossRefPubMed

Yu M, Zhan Q, Finn OJ (2002) Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 38:981–987CrossRefPubMed

Egloff AM, Vella LA, Finn OJ (2006) Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 66:6–9CrossRefPubMed

10.

Kawamoto H, Koizumi H, Uchikoshi T (1997) Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol 150:15–23PubMed

11.

Tran TA, Ross JS, Carlson JA, Mihm MC Jr (1998) Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 29:1085–1090CrossRefPubMed

12.

Ikuerowo SO, Kuczyk MA, Mengel M, van der HE, Shittu OB, Vaske B, Jonas U, Machtens S, Serth J (2006) Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer 119:867–874CrossRefPubMed

13.

Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O (2007) Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 79:210–225CrossRefPubMed

14.

Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313–1323CrossRefPubMed

15.

Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219CrossRefPubMed

16.

Buus S, Lauemoller SL, Worning P, Kesmir C, Frimurer T, Corbet S, Fomsgaard A, Hilden J, Holm A, Brunak S (2003) Sensitive quantitative predictions of peptide-MHC binding by a ‘Query by Committee’ artificial neural network approach. Tissue Antigens 62:378–384CrossRefPubMed

17.

Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O (2003) Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12:1007–1017CrossRefPubMed

18.

Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMed

19.

Elvin J, Potter C, Elliott T, Cerundolo V, Townsend A (1993) A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods 158:161–171CrossRefPubMed

20.

Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS (2000) Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55:519–531CrossRefPubMed

21.

Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163:3812–3818PubMed

22.

Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Odum N (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759–1766CrossRefPubMed

23.

Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, thor Straten P (2005) Immunogenicity of Bcl-2 in patients with cancer. Blood 105:728–734CrossRefPubMed

24.

McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM, Winkelhake J, Spack EG (1997) A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 210:149–166CrossRefPubMed

25.

Trepiakas R, Berntsen A, Hadrup SR, Bjorn J, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM (2010) Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 12(6):721–734CrossRefPubMed

26.

Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, Svane IM (2008) Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 31:771–780CrossRefPubMed

27.

Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH (2007) Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 56:1485–1499CrossRefPubMed

28.

Suzuki H, Graziano DF, McKolanis J, Finn OJ (2005) T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 11:1521–1526CrossRefPubMed

29.

Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ (2009) Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA 106:14010–14015CrossRefPubMed

30.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, tan-Bonnet G, Wolchok JD, Houghton AN (2009) Self-antigen-specific CD8 + T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849–866CrossRefPubMed

Title: Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
Authors: Rikke Sick Andersen
Rikke Bæk Sørensen
Cathrin Ritter
Inge Marie Svane
Jürgen C. Becker
Per thor Straten
Mads Hald Andersen
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 2/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-010-0933-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence

“Tumor immunology meets oncology (TIMO) VI” from 7th to 8th of May 2010 in Halle, Germany

Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer

CDR2 antigen and Yo antibodies

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Keynote webinar | Spotlight on antibody–drug conjugates in cancer